The role of the Hospital Pharmacist: Availability of medicines above price-only procurement
|
|
- Richard Kennedy
- 5 years ago
- Views:
Transcription
1 The role of the Hospital Pharmacist: Availability of medicines above price-only procurement Thijs J. Giezen, PhD, PharmD, MSc Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, Haarlem, the Netherlands Situation in the Netherlands - Exploding drug budgets: 5.86 billion (2014) - Out of hospital: 4.33 billion (growth ca. 3%/ y) - In hospital: 1.53 billion (growth ca. 3-5%/ y) - Increasing pressure due to very expensive oncology drugs - Hospital pharmacist responsible for negotiation with companies 1
2 Price is not everything - Increasing # of drugs not available: - Levothyroxine - BCG intravesical administration - Remifentanyl - Hospital pharmacist spends a couple of hours/ week finding alternatives - A combination of price, delivery reliability and others - Biosimilars have a positive impact on both Use of biosimilars in the Netherlands (I) - Medicines Evaluation Board: - New patients can be treated with a biosimilar right away - Uncontrolled exchange between biological medicines must be avoided. In other words, a patient must receive adequate clinical monitoring and clear instructions - Traceability is important 2
3 Use of biosimilars in the Netherlands (II) - Federation for Medical Specialists: - New patients can be treated with biosimilars - Switching of patients from reference product to biosimilar should be avoided - Switching should preferably be done as part of a controlled study in which efficacy and safety are monitored - Cost savings should not be the major driver to switch Use of biosimilars in the Netherlands (III) - Dutch Society for Rheumatologists: - Switching is possible if there are no signals related to a negative impact on efficacy and safety - Patient has been informed - Efficacy and safety is monitored - In case of diminished efficacy or safety issues the patient must be offered to switch back - Traceability is important - Frequent switching is not recommended 3
4 Role of ministry/ insurance companies - Use of biosimilars is encouraged due to expected savings - Money saved with biosimilars can be spend by the hospital - At this moment: no obligations related to use of biosimilars Biosimilars in clinical practice Misunderstanding and emotions: a bad combination - Concept of biosimilarity is not very well understood - Switching induces antibodies, but patients often switch: - Due to tenders. - Between iv and sc use.. - Patients might induce antibodies after the switch - Disease might progress after the switch Education, Education, Education 4
5 The role of the hospital pharmacist - No personal contact with patients - Better educated to understand the technical aspects of biologicals - Bigger picture regarding the costs of medicines - Role of the hospital pharmacist: traceability - Traceability important for all biologicals - Biologicals prepared in hospital pharmacy: batch # available - Challenges remain for sc administered biologicals: - Barcode controlled administration - Availability of 2D barcodes 5
6 Where is the money going? - Biosimilar leads to price reduction due to competition - However, switching takes time and energy Doctors do not like to be pushed by money arguments Introduction of biosimilars: personal experience - Meeting with rheumatologists and gastroenterologists regarding implementation - Agreed that new patients are being treated with biosimilar - Rheumatologists are going to switch - Patients need to be informed - Gastro-enterologists more reluctant 6
7 Challenges related to use of etanercept - Biosimilar has no powder for injection - Patient need education on use of pen - Biosimilar has no indication for JIA - Traceability is challenging Where is the money going? - Nurses needed to supervise the switch - Incentive for both medical specialist and patient - Savings on biosimilar can be used to create incentive 7
8 Concluding remarks - Switching is safe - Continue to educate medical specialists and nurses and involve patients - Create an incentive to switch Hospital pharmacists are responsible for objective guidance of the choice of biologicals 8
Thijs J Giezen, PharmD, MSc, PhD The Netherlands
Thijs J Giezen, PharmD, MSc, PhD The Netherlands Hospital Pharmacist, Foundation Pharmacy for Hospitals in Haarlem, The Netherlands Member of the Biosimilar Medicinal Product Working Party of European
More informationBiosimilars are interchangeable with their reference products under the supervision of a health care person.
EXTENDING THE USE OF BIOSIMILAR DRUGS: ARE WE WILLING TO ACCEPT THE UNCERTAINTY RELATED TO SWITCHING IN ORDER TO IMPROVE PATIENT ACCESS TO MODERN MEDICINES? Tomas Tesar, PharmD, PhD, MBA, MSc Member of
More informationCURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines
CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE The role of Biosimilar Medicines Marc A. Mahl, MD MBA(INSEAD) President, Medicines for Europe Baltimore, 05 th September 2018 patients quality
More informationHow to maximize patient access Perspectives from The Netherlands
Budapest, June 13, 2018 How to maximize patient access Perspectives from The Netherlands Vs18f13 Arnold G. Vulto PharmD PhD FCP Professor Em. of Hospital Pharmacy & Practical Therapeutics Erasmus University
More informationSurvey 1 - Rheumatoid Arthritis (RA) Patients perception on originator biologics and biosimilars
SUPPLEMENTAL MATERIAL - Perception of originator biologics and biosimilars: a survey amongst Belgian rheumatoid arthritis patients and rheumatologists BioDrugs Eline van Overbeeke 1, Birgit De Beleyr,
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationInnovative Approaches to Saving Patients Money on Prescription Drug Costs
Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices
More informationProfessor Aws Alshamsan, BPharm, RPh, PhD, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationEffective Prescribing Programme - optimising the safe and effective use of biological medicines Case studies
Effective Prescribing Programme - optimising the safe and effective use of biological medicines Case studies Introduction These case studies outline the experiences, challenges and lessons learned to date
More informationRegional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 2
Regional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 2 Adalimumab RMOC Update 1: https://www.sps.nhs.uk/articles/rmoc-briefing-paper-on-adalimumab/ The purpose of
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationConsiderations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab
Considerations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab Head of Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital PhD MD
More informationSubmission to the Department of Health (Fed) regarding. Biosimilar Uptake Drivers Implementation. This joint submission is made by:
Submission to the Department of Health (Fed) regarding Biosimilar Uptake Drivers Implementation This joint submission is made by: The Society of Hospital Pharmacists of Australia (SHPA) SHPA is the national
More informationUniform licensing by EMA followed by patchwork implementation in the European Union when it comes to implementation
Vs15i17 2nd MENA Regulatory conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biosimilars Amman, 17 September 2015 Uniform licensing by EMA followed by patchwork implementation in
More informationNCCP Guidance on the use of Biosimilar Medicines in Cancer Treatment
NCCP Guidance on the use of Biosimilar Medicines in Cancer Treatment Version Date published Amendment Approved By 1 August 2017 Working Group 2 September 2017 Inclusion of link to HPRA information for
More informationWelcome to our 29 th Global GS1 Healthcare Conference. Follow us on Twitter and tweet about the #GS1HCuae
Welcome to our 29 th Global GS1 Healthcare Conference Follow us on Twitter and tweet about the conference! @GS1Healthcare #GS1HCuae GS1 2016 Dr. Ina Trapp Roche Diagnostics Implementation of GS1 barcode
More informationCompetition in the off-patent biological market:
November 14th, 2018 ISPOR Europe, Barcelona Competition in the off-patent biological market: Policies for biosimilars in Europe Evelien Moorkens PhD researcher Market access biosimilars Promotors: prof.
More informationWhat is a reliable source of practical oncology stability data?
What is a reliable source of practical oncology stability data? Pilar Blasco Chief Pharmacist, Valencia General Hospital, Spain Maria Cammarota Director of Pharmacy, Cardarelli Hospital, Naples, Italy
More informationAMCP Webinar Series. Education for Health Care Providers The New Frontier for Biosimilars. How to Ask A Question 8/24/2016.
AMCP Webinar Series Education for Health Care Providers The New Frontier for Biosimilars August 24, 2016 How to Ask A Question Type your question in the Questions area 1 Education for Health Care Providers
More informationHospira at a 5/20/2015. The World s Leading Provider of Injectable Drugs and Infusion Technologies
Sumant Ramachandra, MD, PhD SVP and Chief Scientific Officer Alliance for Health Reform May 20 th, 2015 Hospira at a glance The World s Leading Provider of Injectable Drugs and Infusion Technologies Market
More informationPharmamarketing - strategic challenges
Pharmamarketing - strategic challenges Biomedicine Master Program Lund University Course: Biomedicine the Profession Anna Chérouvrier Hansson, MSc. December 16th, 2014 1. Pharmamarketing - definitions
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationTAKE A CLOSER LOOK at Biosimilars
Key Stakeholders Frequently Asked Questions Executive Summary Understanding Biosimilars Potential Benefits of Biosimilars TAKE A CLOSER LOOK at Biosimilars 2018 Trends in Biosimilars Report Message From
More informationRoche Position 1 on Similar Biotherapeutic Products Biosimilars
Roche Position 1 on Similar Biotherapeutic Products Biosimilars Similar Biotherapeutic Products Biosimilars Innovative biotherapeutic products (e.g.monoclonal antibodies) are losing market exclusivity,
More informationNHS England, National QIPP Delivery Programme, Medicines Management & Optimisation
NHS England, National QIPP Delivery Programme, Medicines Management & Optimisation Biosimilars National Surveys; CCGs and NHS Trusts Summary Report - April 2018 1.0 Background This report summarises the
More informationPharmacy Benefit Drug Trends and Pipeline. Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Dr. Robinson declares no conflicts of interest, real or apparent, and
More informationPharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management
Pharmacy Benefit Drug Trends and Pipeline Casey Robinson, PharmD, MBA, Cigna Pharmacy Management Disclosure and Conflict of Interest Pharmacist Objectives Dr. Robinson declares no conflicts of interest,
More informationUPDATE 2018 CONFERENCE
UPDATE 2018 CONFERENCE Saturday, March 3, 2018 Faculty of Pharmaceutical Sciences 2405 Wesbrook Mall, Vancouver, BC WELCOME This one-day continuing professional development program is targeted to pharmacy
More information2 Pharmacovigilance. 2.1 Fundamentals of Pharmacovigilance
Pharmacovigilance 2 Pharmacovigilance 2 In this chapter, the fundamentals of pharmacovigilance are outlined with a particular emphasis on the role of healthcare professionals in reporting adverse drug
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationBRITISH GENERIC MANUFACTURERS ASSOCIATION
BRITISH GENERIC MANUFACTURERS ASSOCIATION Response by the British Generic Manufacturers Association (BGMA) to the Department of Health Consultation on Amendments to the Statutory Scheme to Control the
More informationNew Indications & Cross- Label Dispensing
New Indications & Cross- Label Dispensing Date: 11/11/2015 Position Paper Executive Summary Innovation is a continuous process, and appropriate incentives are needed to encourage development of the full
More informationIdentification and traceability of biological products. Dr Peter De Veene EU QPPV, Roche On behalf of EBE
Identification and traceability of biological products Dr Peter De Veene EU QPPV, Roche On behalf of EBE Outline Biopharmaceuticals & Pharmacovigilance Traceability & Pharmacovigilance Legal Requirement
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationFACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET
FACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET A study undertaken by GfK Market Access on behalf of the European Biosimilars Group, a sector group of EGA, about the future sustainability
More informationASBM Biosimilars. Canada Prescribers and Biosimilars October, Kevin Olson, CEO Industry Standard Research
ASBM Biosimilars Canada Prescribers and Biosimilars October, 2017 Kevin Olson, CEO Industry Standard Research KevinO@ISRreports.com Table of contents Page 3 Methodology 5 Sample Characteristics 6 Executive
More informationIntroduction of OTC switch in China. Han Qing Regulatory Affairs of One China OTC J&J Oct
Introduction of OTC switch in China Han Qing Regulatory Affairs of One China OTC J&J Oct 22 2014 Outline Regulatory History Classification Switch Challenges Regulatory History 3 stages Stage 1: before
More informationSupply of aseptically - prepared doses of IMPs across legal boundaries. Edition 1. December 2017
Supply of aseptically - prepared doses of IMPs across legal boundaries Edition 1 December 2017 Endorsed and supported by: NHS Pharmaceutical Quality Assurance Committee 2017 with National Pharmacy Clinical
More informationInventory Management: The workshop
Inventory Management: The workshop Youssef N. Akiki PharmD, PharmMBA, DBA candidate OPL CE for Hospital Pharmacists March 4, 2017 Inventory Management Goal Hospital Pharmacist and main tasks Drug inventory
More informationAmerican Heart Association/American Stroke Association Statement on Drug Formularies
American Heart Association/American Stroke Association Statement on Drug Formularies Underlined terms are defined on page 4 of the document. 1. The AHA supports a formulary system that: Assures access
More information12/10/2011. Development of sterile medicinal products in Dutch hospital pharmacy SEHP Santiago de Compostella. Introduction.
Development of sterile medicinal products in Dutch hospital pharmacy SEHP 2011 Santiago de Compostella Introduction Willem Meulenhoff (1971) Production Pharmacist at NV Organon (MSD) Head of the Production
More informationImplementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank
Implementation of Pharmaceutical Policy Reform Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Sector issues Critical sector for health outcomes Characterized by market
More informationBIOSIMILAR AWARENESS INITIATIVE PROJECT MANAGEMENT PLAN
BIOSIMILAR AWARENESS INITIATIVE PROJECT MANAGEMENT PLAN Date: June 2016 This document and its attachments are UNCLASSIFIED PRINCE2 Project Initiation Documentation TABLE OF CONTENTS 1 PROJECT DEFINITION...
More informationBY THE BLESSINGS OF ALMIGHTY GOD THE MINISTER OF HEALTH OF THE REPUBLIC OF INDONESIA,
REGULATION OF THE MINISTER OF HEALTH OF THE REPUBLIC OF INDONESIA NUMBER 3 OF 2015 ON CIRCULATION, STORAGE, DESTRUCTION AND REPORTING OF NARCOTICS, PSYCHOTROPICS AND PHARMACY PRECURSORS BY THE BLESSINGS
More informationBetter Access, Better Health A guide to the generic and biosimilars medicines market and pricing
Better Access, Better Health A guide to the generic and biosimilars medicines market and pricing Section 1: About the BGMA & Generics The British Generic Manufacturers Association (BGMA) is made up of
More informationApplication for registration certificate to operate a retail pharmacy 5, ,000.00
Appendix 3: Pharmaceutical Regulatory Authority Schedule of Fees, 2010 A. RETAIL / HOSPITAL PHARMACY FEE UNITS (1 fee Unit = K180) APPLICATION FEES (ZMK) 1 2 Application for registration certificate to
More informationBIOSIMILARS: How Do They Affect Patient Care and Safety?
BIOSIMILARS: How Do They Affect Patient Care and Safety? Josie Garnoc, MSN, RN, CRNI, OCN Director of Nursing, Beaumont Hospital-Grosse Pointe Grosse Pointe, Michigan Disclosure Statement Nothing to Disclose
More informationStandard Operating Procedures
Standard Operating Procedures 5.14.1 Investigational Product Handling and Storage History Version Date Author Reason 1.1 23 rd August B Fazekas New procedure 2007 1.2 16 th October 2007 B Fazekas Update
More informationRe: Therapeutic Goods Administration, Consultation: Nomenclature of Biological Medicines
September 7, 2017 Biological Science Section Therapeutic Goods Administration (TGA) PO Box 100 Woden ACT 2606 Re: Therapeutic Goods Administration, Consultation: Nomenclature of Biological Medicines Dear
More informationCLINICAL TRIALS AND MARKET RESEARCH
CLINICAL TRIALS AND MARKET RESEARCH AAKP's role in Clinical Trials and Market Research AAKP supports innovation in the kidney space. We are actively involved in market research - to share the patient voice
More informationTendering for Medicines and Services with CMU. Kevan Wind, Medicines Procurement Specialist Pharmacist, London & East of England
Tendering for Medicines and Services with CMU Kevan Wind, Medicines Procurement Specialist Pharmacist, London & East of England What we will cover 1. Pricing and Procurement of Medicines in the NHS. 2.
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationDr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority
CHALLENGES AND OPPORTUNITIES IN COLD CHAIN: HEALTH CARE RELATED DRIVERS Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority AGENDA Integrating stakeholders
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationRole of HIT Vendors in Promoting Safe Use of Biosimilars
Role of HIT Vendors in Promoting Safe Use of Biosimilars Session #312, February 22, 2017 Stella Stergiopoulos, MS, MPH; Senior Project Manager, Tufts CSDD Thomas Felix, MD, Medical Director, R&D Policy;
More informationMedicines optimisation & the model hospital
Medicines optimisation & the model hospital - Securing value from medicines Andrew Davies, Professional Lead for Hospital Pharmacy, NHS Improvement Andrew.davies@nhs.net @HospChiefPharm Commissioning Chemotherapy
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationRe: Docket Number FDA-2017-D-0154 Considerations in Demonstrating Interchangeability With a Reference Product; Guidance for Industry, Draft Guidance
PO Box 3691 Arlington, VA 22203 (703) 971-1700 May 22, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration Department of Health and Human Services 5630 Fishers Lane, Room 1061 Rockville,
More informationThe need for generic policies as part of health reform
The need for generic policies as part of health reform Richard Laing EMP/WHO for PPRI Conference Vienna September 30 th 2011 The US Generics Market reaches $107.5bn with growth four times higher than total
More informationPurchasing for Safety Policy for Pharmaceuticals January Page 1 of 8 (Purchasing for Safety Policy for Pharmaceuticals)
Purchasing for Safety Policy for s January 2010 Page 1 of 8 (Purchasing for Safety Policy for s) Policy Title Purchasing for Safety Policy for s Policy Reference Number Acute10/006 Implementation Date
More informationBUSTERSYSTEM. Clinical and Logistics Management of Drugs
BUSTERSYSTEM Clinical and Logistics Management of Drugs 3 BUSTER SYSTEM The complete and innovative solution for the management of drugs in hospitals: simple, modular, reliable BUSTER SYSTEM is a clever
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationRx EDGE. Retail strategy considerations for the launch of a new product or indication. White Paper. Pharmacy Networks
Retail strategy considerations for the launch of a new product or indication White Paper Introduction One of the most difficult and stressful marketing decisions in pharmaceutical new product launches
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationTHE BIOLOGIC DRUG MARKET. ebook: The current state of biologic drugs and the challenges ahead
THE BIOLOGIC DRUG MARKET 2 0 1 7 HOW DO DRUGS AND BIOLOGICS DIFFER? This ebook answers that question, and so much more. OptumRx has summarized the complex and expensive world of biologic drugs for you.
More informationThe introduction of biosimilars into clinical practice
Commissioning Chemotherapy Services The introduction of biosimilars into clinical practice Jatinder Harchowal Chief Pharmacist / Clinical Director Royal Marsden NHS Foundation Trust Medicines lead for
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationDevelopments in Operational Procurement Efficiency. Sarah Griffiths Pharmacy Procurement Lead July 2017
Developments in Operational Procurement Efficiency Sarah Griffiths Pharmacy Procurement Lead July 2017 Aims of the Session GS1 Scan4Safety and PEPPOL The Scan4Safety and PEPPOL principles? What does purchase
More informationACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma
ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN Presentation to UN 2018 Public Service Forum Richard Bergström External Lead Pharma Enabling trust 1 SICPA: GLOBAL ROLE Protection of 85+% world currency
More informationClinical Category Lead - Clinical Product Co-ordination
Principles Vision Purpose Statement Clinical Category Lead - Clinical Product Co-ordination healthalliance Purpose, Vision and Principles healthalliance provides shared services to benefit NZ health organisations.
More informationBiosimilars: The Impact on Academic Pharmacy
Biosimilars: The Impact on Academic Pharmacy George E. MacKinnon III, PhD, MS, RPh, FASHP Founding Dean and Professor College of Pharmacy Vice Provost for Health Sciences Roosevelt University Learning
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More information34 th Annual J.P. Morgan Healthcare Conference
34 th Annual J.P. Morgan Healthcare Conference Vincent A. Forlenza Chairman, Chief Executive Officer and President January 13, 2016 Forward-Looking Statements These materials include forward-looking statements
More informationStatement on Drug Pricing in America: A Prescription for Change. Submitted to the Senate Finance Committee
Statement on Drug Pricing in America: A Prescription for Change Submitted to the Senate Finance Committee January 29, 2019 America s Health Insurance Plans (AHIP) is the national association whose members
More information10/06/2016. Sustainable biosimilar policies. Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik.
Sustainable biosimilar policies Panel discussion - Joint 22 nd Medicines for Europe and 19 th IGBA Annual Conference in Dubrovnik June 9, 2016 Michael Dilger Matthias Liefner Mark Kastner Nicklas Jacobsen
More informationEthical approaches to Innovation in Global Health
Georg Marckmann Institute of Ethics, History and Theory of Medicine Ethical approaches to Innovation in Global Health World Health Summit Satellite Event Innovation in Health: The contribution of biologic
More informationA GUIDE TO THIS REFLECTIONS B RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE
A GUIDE TO THIS REFLECTIONS B327-02 RESEARCH STUDY IF YOU RE FIGHTING BREAST CANCER, YOU RE NOT ALONE Do you have breast cancer that has spread to outside the breast? Has your tumor tested positive for
More informationBi Regional Consultation on Good Governance
Pharmaceutical Services Ministry of Health Malaysia GGM PROGRAMME IN MALAYSIA WHO Collaborating Centre For Regulatory Control of Pharmaceuticals Bi Regional Consultation on Good Governance 9 th November
More informationBiosimilars an update
Biosimilars an update Darren Roberts Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Clinical pharmacology and toxicology, St Vincent s Hospital (Sydney) Nephrology,
More informationLast Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4
STANDARD OPERATING PROCEDURE (SOP) FOR CLINICAL RESEARCH Title: Investigational Drug Billing Last Revised: 3/2018 Prior Version: 12/2014 SOP NUMBER: SS-304 Page 1 of 4 1. PURPOSE: To assure accurate and
More informationHow to treat more patients and make money in emerging markets
1 How to treat more patients and make money in emerging markets AUTHOR Raja Shankar RShankar@imscg.com People buy innovative products in emerging markets. Millions of Brazilians, Russians, Indians, Chinese,
More informationStrategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002
Strategic trends facing the pharmaceutical industry and their implications for marketing skills development Received: 4th September, 2002 Gill Butler has worked in the pharmaceutical industry for 21 years,
More informationProfessor Kimme Hyrich, MD, PhD, FRCPC, UK
GaBI Scientific Meetings 26 January 2017, Pullman London St Pancras, London, UK ROUNDTABLE ON REGISTRIES Practical Considerations for Registries making them work Professor Kimme Hyrich, MD, PhD, FRCPC,
More informationProfessor Francisco José de Abajo, MD, MPH, PhD, Spain
GaBI Scientific Meetings ROUNDTABLE ON BIOSIMILARS Pharmacovigilance, Traceability, Immunogenicity 15 November 2016, Real Academia Nacional de Farmacia, Madrid, Spain Professor Francisco José de Abajo,
More informationClinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View)
Athens, May 25, 2018 Clinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View) Vs18e28 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy &
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationInnovations in Drug Pricing and Reimbursement:
ADVISORY REPORT AM PL E PA G ES S A S G ES A FirstWord Dossier Advisory report and Reimbursement Published Copyright 2016 Doctor s Guide Publishing Limited Part of the FirstWord Dossier family of reports
More informationWhy is Healthcare Stuck in Reporting?
Roundtable Discussion Why is Healthcare Stuck in Reporting? April 2013 Moderated by: Bryan Engle should be directed to members@. Overview Understanding and obtaining the benefits of advanced analytics
More informationBiosimilar Medicines: A National Prescribing Framework. May 2015
Biosimilar Medicines: A National Prescribing Framework May 2015 Healthcare Improvement Scotland 2015 First published May 2015 Healthcare Improvement Scotland is committed to equality and diversity. We
More informationTestimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC
Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018
More informationThe Future of Pharmaceutical Quality
The Future of Pharmaceutical Quality First SQA/BIRS Center Meeting Purdue University Polytechnic Institute Louis W. Yu, Ph.D. Chief Quality Officer Unique Challenges of the Pharmaceutical Industry a. The
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationOverview of Biologics (Including Biosimilars)
Overview of Biologics (Including Biosimilars) 2015 Sandoz Inc. All Rights Reserved. The material contained in this slide deck may not be altered or reproduced without express written consent from Sandoz
More informationWe Love Drugs. We Use Drugs
Where s It Coming From? Counterfeits and Pharmaceutical Pedigree Bryan A. Liang, MD, PhD, JD San Diego Center for Patient Safety University of California, San Diego School of Medicine Institute of Health
More informationWHITE PAPER ON. Public Procurement of Biological Medicines
WHITE PAPER ON Public Procurement of Biological Medicines JUNE 2015 Table of contents 1. 2. 3. 4. 4.1. 4.2. 4.3. 4.3.1 4.3.2 Executive summary Introduction EU policy framework Procurement of biological
More informationThe pessimist sees difficulty in every opportunity, the optimist sees the opportunity in every difficulty. Churchill, Winston
The pessimist sees difficulty in every opportunity, the optimist sees the opportunity in every difficulty. Churchill, Winston Expectations are same: Safety Efficicacy GMP compliance Profile attribute Population
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More information